Gastrointestinal Therapeutics Market (By Type; By Drug Class; By Application: Crohn’s Disease, Ulcerative Colitis, GERD; By Route Of Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Gastrointestinal Therapeutics Market 

5.1. COVID-19 Landscape: Gastrointestinal Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Gastrointestinal Therapeutics Market, By Type

8.1. Gastrointestinal Therapeutics Market, by Type, 2023-2032

8.1.1. Branded

8.1.1.1. Market Revenue and Forecast (2019-2032)

8.1.2. Generics

8.1.2.1. Market Revenue and Forecast (2019-2032)

Chapter 9. Global Gastrointestinal Therapeutics Market, By Drug Class

9.1. Gastrointestinal Therapeutics Market, by Drug Class, 2023-2032

9.1.1. Aminosalicylates

9.1.1.1. Market Revenue and Forecast (2019-2032)

9.1.2. Digestive enzymes

9.1.2.1. Market Revenue and Forecast (2019-2032)

9.1.3. Proton Pump Inhibitors

9.1.3.1. Market Revenue and Forecast (2019-2032)

9.1.4. Laxatives

9.1.4.1. Market Revenue and Forecast (2019-2032)

9.1.5. Anti-Emetics

9.1.5.1. Market Revenue and Forecast (2019-2032)

9.1.6. H2 Antagonists

9.1.6.1. Market Revenue and Forecast (2019-2032)

9.1.7. Anti-Diarrheal

9.1.7.1. Market Revenue and Forecast (2019-2032)

9.1.8. Biologics/Biosimilar

9.1.8.1. Market Revenue and Forecast (2019-2032)

9.1.9. Others

9.1.9.1. Market Revenue and Forecast (2019-2032)

Chapter 10. Global Gastrointestinal Therapeutics Market, By Route of Administration 

10.1. Gastrointestinal Therapeutics Market, by Route of Administration, 2023-2032

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2019-2032)

10.1.2. Injectable

10.1.2.1. Market Revenue and Forecast (2019-2032)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2019-2032)

Chapter 11. Global Gastrointestinal Therapeutics Market, By Application

11.1. Gastrointestinal Therapeutics Market, by Application, 2023-2032

11.1.1. Crohn's disease

11.1.1.1. Market Revenue and Forecast (2019-2032)

11.1.2. Ulcerative colitis

11.1.2.1. Market Revenue and Forecast (2019-2032)

11.1.3. GERD

11.1.3.1. Market Revenue and Forecast (2019-2032)

11.1.4. IBS

11.1.4.1. Market Revenue and Forecast (2019-2032)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2019-2032)

Chapter 12. Global Gastrointestinal Therapeutics Market, By Distribution Channel

12.1. Gastrointestinal Therapeutics Market, by Distribution Channel, 2023-2032

12.1.1. Hospital Pharmacies

12.1.1.1. Market Revenue and Forecast (2019-2032)

12.1.2. Retail Pharmacies

12.1.2.1. Market Revenue and Forecast (2019-2032)

12.1.3. Online Pharmacies

12.1.3.1. Market Revenue and Forecast (2019-2032)

Chapter 13. Global Gastrointestinal Therapeutics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Type (2019-2032)

13.1.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.1.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.1.4. Market Revenue and Forecast, by Application (2019-2032)

13.1.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Type (2019-2032)

13.1.6.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.1.6.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.1.6.4. Market Revenue and Forecast, by Application (2019-2032)

13.1.7. Market Revenue and Forecast, by Distribution Channel (2019-2032) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Type (2019-2032)

13.1.8.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.1.8.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.1.8.4. Market Revenue and Forecast, by Application (2019-2032)

13.1.8.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Type (2019-2032)

13.2.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.2.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.2.4. Market Revenue and Forecast, by Application (2019-2032) 

13.2.5. Market Revenue and Forecast, by Distribution Channel (2019-2032) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Type (2019-2032)

13.2.6.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.2.6.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.2.7. Market Revenue and Forecast, by Application (2019-2032) 

13.2.8. Market Revenue and Forecast, by Distribution Channel (2019-2032) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Type (2019-2032)

13.2.9.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.2.9.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.2.10. Market Revenue and Forecast, by Application (2019-2032)

13.2.11. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Type (2019-2032)

13.2.12.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.2.12.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.2.12.4. Market Revenue and Forecast, by Application (2019-2032)

13.2.13. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Type (2019-2032)

13.2.14.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.2.14.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.2.14.4. Market Revenue and Forecast, by Application (2019-2032)

13.2.15. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Type (2019-2032)

13.3.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.3.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.3.4. Market Revenue and Forecast, by Application (2019-2032)

13.3.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Type (2019-2032)

13.3.6.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.3.6.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.3.6.4. Market Revenue and Forecast, by Application (2019-2032)

13.3.7. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Type (2019-2032)

13.3.8.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.3.8.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.3.8.4. Market Revenue and Forecast, by Application (2019-2032)

13.3.9. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Type (2019-2032)

13.3.10.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.3.10.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.3.10.4. Market Revenue and Forecast, by Application (2019-2032)

13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Type (2019-2032)

13.3.11.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.3.11.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.3.11.4. Market Revenue and Forecast, by Application (2019-2032)

13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Type (2019-2032)

13.4.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.4.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.4.4. Market Revenue and Forecast, by Application (2019-2032)

13.4.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Type (2019-2032)

13.4.6.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.4.6.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.4.6.4. Market Revenue and Forecast, by Application (2019-2032)

13.4.7. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Type (2019-2032)

13.4.8.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.4.8.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.4.8.4. Market Revenue and Forecast, by Application (2019-2032)

13.4.9. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Type (2019-2032)

13.4.10.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.4.10.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.4.10.4. Market Revenue and Forecast, by Application (2019-2032)

13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Type (2019-2032)

13.4.11.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.4.11.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.4.11.4. Market Revenue and Forecast, by Application (2019-2032)

13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Type (2019-2032)

13.5.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.5.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.5.4. Market Revenue and Forecast, by Application (2019-2032)

13.5.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Type (2019-2032)

13.5.6.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.5.6.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.5.6.4. Market Revenue and Forecast, by Application (2019-2032)

13.5.7. Market Revenue and Forecast, by Distribution Channel (2019-2032)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Type (2019-2032)

13.5.8.2. Market Revenue and Forecast, by Drug Class (2019-2032)

13.5.8.3. Market Revenue and Forecast, by Route of Administration (2019-2032)

13.5.8.4. Market Revenue and Forecast, by Application (2019-2032)

13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2019-2032)

Chapter 14. Company Profiles

14.1. AbbVie Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. AstraZeneca

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Janssen Pharmaceuticals NV

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Sun Pharmaceutical Industries Ltd.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Takeda Pharmaceutical Company Limited

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Salix Pharmaceuticals

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Pfizer Inc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Bayer AG

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Abbott

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Cipla Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms